Background: Single isomers of the selective serotonin reuptake inhibitors citalopram (escitalopram, S-citalopram) and fluoxetine (R-fluoxetine) are currently under development for the treatment of depression and other psychiatric disorders. Previous studies conducted in laboratory animals have revealed that the biological effects on serotonin reuptake for citalopram reside in the S enantiomer. In contrast, both enantiomers of fluoxetine contribute to its biological activity.
Methods: In the present study, the potency and selectivity of escitalopram, R-fluoxetine, and all of the other currently available selective serotonin reuptake inhibitors were compared for binding affinity at the human serotonin, norepinephrine, and dopamine transporters and several select neurotransmitter receptors using radioligand binding assays.
Results: Both escitalopram and R-fluoxetine were potent inhibitors of the serotonin transporter (Ki = 1.1 and 1.4 nmol/L, respectively). Escitalopram was the most serotonin transporter-selective compound tested and was ∼30-fold more potent than R-citalopram.
Conclusions: As noted previously, paroxetine and sertraline possess moderate affinity (<50 nmol/L) for the human norepinephrine transporter and dopamine transporter, respectively. R-Fluoxetine, unlike the other selective serotonin reuptake inhibitors, possesses moderate affinity (Ki = 64 nmol/L) for the serotonin 2C receptor. Potential clinical correlates of these unique attributes of escitalopram and R-fluoxetine are discussed.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Biological Psychiatry
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- A review of central 5-HT receptors and their function.Neuropharmacology. 1999; 38: 1083-1152
- Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes.Life Sci. 1993; 52: 1023-1029
- Plasma levels of citalopram enatiomers and metabolites in elderly patients.Psychopharmacol Bull. 1997; 33: 109-112
- Comparison of norfluoxetine enatiomers as serotonin uptake inhibitors in vivo.Neuropharmacology. 1992; 31: 997-1000
- The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer.J Neural Transm. 1992; 88: 157-160
- Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac).Proc Natl Acad Sci U S A. 1997; 94: 2036-2040
- Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.J Pharmacol Exp Ther. 1997; 283: 1305-1322
- Seproxetine.Pharmacologist. 1991; 33: 219
- Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor.J Med Chem. 1988; 31: 1412-1417
- Analysis of enatiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography.Ther Drug Monit. 1995; 17: 273-279
- Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes.Pharmacogenetics. 1997; 7: 1-10
- The antidepressant effect of citalopram resides in the S-enantiomer (Lu 26-054).Biol Psychiatry. 2000; 47: 88S
- Interaction of the enatiomers of fluoxetine and norfluoxetine with human liver cytochromes P450.J Pharmacol Exp Ther. 1993; 266: 964-971
- Pharmacological profile of antidepressants and related compounds at human monoamine transporters.Eur J Pharmacol. 1997; 340: 249-258
- Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors.Neuropsychopharmacology. 1991; 5: 43-47
Accepted: March 8, 2001
Received in revised form: February 28, 2001
Received: November 28, 2000
© 2001 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.